Heron Therapeutics, Inc. (LON: 0J4V)
London
· Delayed Price · Currency is GBP · Price in USD
1.692
+0.052 (3.15%)
Jan 23, 2025, 2:33 PM BST
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $32.81M USD in the quarter ending September 30, 2024, with 4.38% growth. This brings the company's revenue in the last twelve months to $137.74M, up 12.13% year-over-year. In the year 2023, Heron Therapeutics had annual revenue of $127.04M with 17.99% growth.
Revenue (ttm)
$137.74M
Revenue Growth
+12.13%
P/S Ratio
n/a
Revenue / Employee
$1.09M
Employees
126
Market Cap
201.29M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
Dec 31, 2019 | 145.97M | 68.49M | 88.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Heron Therapeutics News
- 4 weeks ago - Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina - PRNewsWire
- 7 weeks ago - Relief For Heron Therapeutics After The Court Win On Cinvanti - Seeking Alpha
- 7 weeks ago - U.S. District Court Upholds Validity of CINVANTI® Patents - PRNewsWire
- 2 months ago - Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - PRNewsWire
- 2 months ago - Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - PRNewsWire
- 3 months ago - Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - PRNewsWire
- 3 months ago - Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - PRNewsWire